Baisong Mei - 02 Mar 2024 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Reporting relationship: SVP, CHIEF MEDICAL OFFICER
Issuer ticker: EDIT
Reported as of: 02 Mar 2024
Net transaction value: -$191,425
SEC form: 4
Accepted by SEC: 05 Mar 2024, 19:54:42 UTC
Prior SEC filing: 21 Jul 2023
Next SEC filing: 06 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Baisong Mei

Key filing fact

Baisong Mei filed Form 4 for Editas Medicine, Inc. (EDIT) on 05 Mar 2024.

Key facts

This page summarizes Baisong Mei's Form 4 filing for Editas Medicine, Inc. (EDIT).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2024, 19:54.

Change

Previous filing in this sequence was filed on 21 Jul 2023.
Current net transaction value: -$191,425.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EDIT transaction

Common Stock

Award

Transaction value: $0
Shares: +50,900
Change %: +71%
Price: $0.000000
Shares after: 122,955
Date: 02 Mar 2024
Ownership: Direct
Footnotes: F1

EDIT transaction

Common Stock

Award

Transaction value: $0
Shares: +19,458
Change %: +16%
Price: $0.000000
Shares after: 142,413
Date: 02 Mar 2024
Ownership: Direct
Footnotes: F2

EDIT transaction

Common Stock

Award

Transaction value: $0
Shares: +19,457
Change %: +14%
Price: $0.000000
Shares after: 161,870
Date: 02 Mar 2024
Ownership: Direct
Footnotes: F3

EDIT transaction

Common Stock

Sale

Transaction value: $191,425
Shares: -20,327
Change %: -13%
Price: $9.42
Shares after: 141,543
Date: 04 Mar 2024
Ownership: Direct
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EDIT transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +152,800
Change %
Price: $0.000000
Shares after: 152,800
Date: 02 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 152,800
Exercise price: $10.53
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028.

Footnote F2

Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 18, 2022.

Footnote F3

Reflects the vesting, upon the achievement of a business development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 18, 2022.

Footnote F4

Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022 and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2024. The sale does not represent a discretionary trade by the Reporting Person.

Footnote F5

This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Footnote F6

This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.